Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 781 to 790 of 862 total matches.

Treatment of Community-Associated MRSA Infections

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
Methicillin-resistant Staphylococcus aureus (MRSA) infections, which have been a concern for many years, previously occurred primarily in hospitalized patients and those recently treated with antibiotics. In the past few years, there has been an increasing incidence worldwide of community-associated (CA) MRSA infections in patients without recent antibiotic exposure or contact with the healthcare system.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):13-4 |  Show IntroductionHide Introduction

Abatacept (Orencia) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Med Lett Drugs Ther. 2006 Feb 27;48(1229):17-8 |  Show IntroductionHide Introduction

Anidulafungin (Eraxis) for Candida Infections

   
The Medical Letter on Drugs and Therapeutics • May 22, 2006  (Issue 1235)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
Anidulafungin (ay nid yoo la fun jin; Eraxis - Pfizer), a third intravenous echinocandin antifungal, has been approved by the FDA for treatment of esophageal candidiasis, candidemia, and other complicated Candida infections (intra-abdominal abscess or peritonitis).
Med Lett Drugs Ther. 2006 May 22;48(1235):43-4 |  Show IntroductionHide Introduction

Transdermal Methylphenidates (Daytrana) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49-51 |  Show IntroductionHide Introduction

Insulin Detemir (Levemir), a New Long-Acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus), the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting...
Med Lett Drugs Ther. 2006 Jul 3;48(1238):54-5 |  Show IntroductionHide Introduction

Fish Oil Supplements

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2006  (Issue 1239)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential human nutrients. The main dietary source of PUFAs is fatty fish such as salmon, but small amounts may be converted from α-linolenic acid in nuts, seeds, and plant oils such as canola or flaxseed oil. An increased intake of these fatty acids has been shown to modify membrane function, inhibit thrombus formation, decrease inflammation, lower plasma triglycerides, and alter the electrical activity of the myocardium.
Med Lett Drugs Ther. 2006 Jul 17;48(1239):59-60 |  Show IntroductionHide Introduction

Proton Pump Inhibitors for GERD in Children

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007  (Issue 1255)
Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons ...
A recent advertisement for the proton pump inhibitor (PPI) lansoprazole (Prevacid - TAP) suggests that children who cough at night, complain of abdominal pain, refuse to eat, or have a bad taste in their mouths may all have gastroesophageal reflux disease (GERD). A Bunny's Tummy Trouble, a children's book about GERD published by TAP, is now available as a patient handout in pediatricians' waiting rooms. The use of acid-suppressive drugs in infants and children has increased markedly in recent years and many of these drugs are now available in child-friendly formulations. A table in the article...
Med Lett Drugs Ther. 2007 Feb 26;49(1255):17-8 |  Show IntroductionHide Introduction

Two New Drugs for Renal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007  (Issue 1255)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Sunitinib (Sutent - Pfizer) and sorafenib (Nexavar - Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC). Sunitinib is also approved for use in patients with gastrointestinal stromal tumor (GIST) who are not responding to or are intolerant of standard therapy with imatinib (Gleevec).
Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20 |  Show IntroductionHide Introduction

Paliperidone (Invega) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007  (Issue 1256)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.
Med Lett Drugs Ther. 2007 Mar 12;49(1256):21-3 |  Show IntroductionHide Introduction

MoviPrep: A New Bowel Prep for Colonoscopy

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional cathartic and flavoring agent, and requires a lower volume of fluid (3 L compared to the traditional 4 L) than most other PEG products. HalfLytely is an FDA-approved 2-L PEG product, but it must be taken with bisacodyl.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):47-8 |  Show IntroductionHide Introduction